Diabetes & metabolism最新文献

{"title":"Equivalent fracture odds do not define equivalent treatment thresholds in diabetes","authors":"Yong Zhu,&nbsp;Jinjin Luo,&nbsp;Sheng Zheng","doi":"10.1016/j.diabet.2026.101764","DOIUrl":"10.1016/j.diabet.2026.101764","url":null,"abstract":"<div><div>None.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 3","pages":"Article 101764"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147825575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between primary bile acids and metabolically unhealthy obesity","authors":"Mingxi Zong ,&nbsp;Chao Wu ,&nbsp;Shaoqian Zhao ,&nbsp;Lijie Kong ,&nbsp;Wen Li ,&nbsp;Juan Shi ,&nbsp;Yufei Chen ,&nbsp;Yaorui Ye ,&nbsp;Aibo Gao ,&nbsp;Guang Ning ,&nbsp;Weiqing Wang ,&nbsp;Jiqiu Wang ,&nbsp;Weiqiong Gu ,&nbsp;Jie Hong ,&nbsp;Ruixin Liu","doi":"10.1016/j.diabet.2026.101761","DOIUrl":"10.1016/j.diabet.2026.101761","url":null,"abstract":"<div><h3>Objective</h3><div>Dysregulation of bile acid (BA) profiles is closely associated with obesity and its related metabolic abnormalities. This study aims to investigate the BA alterations between metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) and identify specific BA species associated with MUO.</div></div><div><h3>Methods</h3><div>We measured serum bile acid profiles in two cross-sectional studies. The discovery cohort included 261 normal-weight, 80 MHO, and 120 MUO individuals. The validation cohort, consisting of 104 MHO and 104 MUO participants (matched for age, sex, and BMI), was used for confirmation.</div></div><div><h3>Results</h3><div>Individual primary bile acids (PBAs), including cholic acid, glycocholic acid, chenodeoxycholic acid, and total PBA concentration, were markedly increased in MUO compared with both normal-weight and MHO subjects. Total secondary bile acids were decreased in both obesity phenotypes compared with normal-weight subjects, but did not differ between MUO and MHO. Among individuals with obesity, either individual PBA or total PBA levels were positively correlated with metabolic deterioration parameters such as WHR, HOMA-IR, HbA1c, and TG. Moreover, a higher total PBA level was associated with an increased proportion of MUO. These findings were further replicated in the validation cohort.</div></div><div><h3>Conclusions</h3><div>Serum individual PBAs and total PBAs were significantly elevated in MUO compared with MHO. Higher PBA levels were associated with adverse metabolic parameters and an increased proportion of MUO. This study characterizes the distinct BA profiles across obesity phenotypes and highlights the associations between PBAs and MUO.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 3","pages":"Article 101761"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147719301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why glycemic control remains suboptimal in type 1 diabetes in the era of advanced technologies?","authors":"Michael Joubert","doi":"10.1016/j.diabet.2026.101763","DOIUrl":"10.1016/j.diabet.2026.101763","url":null,"abstract":"<div><div>Type 1 diabetes (T1D) remains associated with suboptimal glycemic control in a substantial proportion of individuals despite major advances in insulin formulations and technological systems. This apparent paradox highlights that glucose control in T1D is not determined by technology alone, but rather emerges from the interaction of multiple biological, therapeutic, behavioral, and psychosocial factors. In this structured narrative review, we examine the main determinants that continue to limit optimal control in real-world practice. Pathophysiological barriers include residual or absolute insulin deficiency, impaired counterregulatory responses, chronic or acute insulin resistance, hormonal changes related to puberty, the menstrual cycle and pregnancy, physical activity, and advanced renal disease. Therapeutic and technological progress has improved glycemic safety and time in range, yet insulin therapy remains an imperfect substitute for physiological insulin secretion, and the effectiveness of CGM, insulin pumps, connected pens, and AID systems remains highly dependent on sustained and appropriate use. Behavioral determinants such as treatment adherence, meal bolusing, carbohydrate estimation, physical activity management, and technology misuse continue to be major drivers of glycemic variability. In parallel, psychosocial factors, including eating disorders, anxiety, depression, stress, socioeconomic vulnerability, and shift work, strongly influence self-management and may further aggravate metabolic instability. These determinants interact dynamically and bidirectionally, creating self-reinforcing cycles that help explain why recommended glycemic targets remain difficult to achieve. Improving outcomes in T1D therefore requires moving beyond a technology-centered model toward an integrated, patient-centered approach that combines technological innovation with therapeutic education, psychosocial screening, and individualized care across the life course.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 3","pages":"Article 101763"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147825584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone phenotype in familial partial lipodystrophy type 2: Insulin resistance and sclerostin","authors":"Hippolyte Dupuis ,&nbsp;Arnaud Jannin ,&nbsp;Lucille Van Es ,&nbsp;Romain Vankemmel ,&nbsp;Olivier Ernst ,&nbsp;Pascal Pigny ,&nbsp;Georges Lion ,&nbsp;Benjamin Chevalier ,&nbsp;Bernard Cortet ,&nbsp;Stéphanie Espiard ,&nbsp;Marie-Christine Vantyghem","doi":"10.1016/j.diabet.2026.101762","DOIUrl":"10.1016/j.diabet.2026.101762","url":null,"abstract":"<div><h3>Background</h3><div>The impact of insulin-resistance on bone mineral density (BMD) remains unclear. Sclerostin inhibits bone formation, and increases with ageing, metabolic syndrome, and renal failure. Genetically-determined low sclerostin levels are associated with high BMD. Our aim was to determine the bone phenotype and the influence of insulin-resistance without obesity on sclerostin levels in Familial Partial Lipodystrophy type 2 (FPLD2).</div></div><div><h3>Methods</h3><div>Demographic, metabolic, anthropometric, and bone parameters were compared after adjustment on age and menopausal status across four groups of women (19 FPLD2, 12 obese with diabetes, 14 obese without diabetes, 11 lean controls).</div></div><div><h3>Results</h3><div>The FPLD2 group had significantly higher Intra-Abdominal/Total-Abdominal Fat (IAF/TAF) ratio and lower fat mass percentage compared to the other groups. Glucose parameters (Fasting blood glucose, C-peptide, HbA1c, HOMA2-IR_CP), and triglycerides were significantly higher in the FPLD2 group than in controls, with a higher sclerostin level. Sclerostin levels were positively associated with age, glucose parameters, Z-score, T-score, and negatively with osteocalcin. FPLD2 was the only subgroup in which the association between sclerostin and HOMA2-IR_CP was maintained. In contrast, osteocalcin levels were negatively associated with age, glucose parameters, triglycerides, IAF/TAF, and bone parameters. Neither sclerostin or osteocalcin were associated with BMI, whole-body fat, or leptin.</div></div><div><h3>Conclusion</h3><div>The association of sclerostin (positive) and osteocalcin (negative) with HOMA2-IR_CP, but not with fat mass parameters, suggests a predominant role of insulin-resistance over fat mass in the regulation of osteokines. Insulin-resistance may uncouple the usual relationship between sclerostin and BMD. The sclerostin contribution in early atherosclerosis in FPLD2 remains to be studied.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 3","pages":"Article 101762"},"PeriodicalIF":4.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147793857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards humane diabetes care in the era of technological innovation","authors":"Gérard Reach","doi":"10.1016/j.diabet.2026.101745","DOIUrl":"10.1016/j.diabet.2026.101745","url":null,"abstract":"<div><div>This editorial argues that technological innovation in diabetes, particularly continuous glucose monitoring and hybrid closed-loop systems, must be integrated into a humane medicine centred on both metrics and persons. It was written under the pressure of observing that diabetes distress persists in a substantial proportion of patients who benefit from the most advanced technologies, including hybrid closed‑loop systems. The author describes each patient’s situation as a “mental puzzle” of beliefs, emotions and social constraints and highlights the biographical ruptures caused by disease and technology. The clinical encounter has a double object—the disease and the person—held together through clinical conversation that translates innovation into livable choices for each individual. It is where technicality meets humanity.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101745"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147370934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telemedicine-based diabetic retinopathy screening in patients over 70 Years: a French cohort study within the OPHDIAT network","authors":"Héloïse Torres-Villaros ,&nbsp;Joseph Albou ,&nbsp;Franck Fajnkuchen ,&nbsp;Aude Couturier ,&nbsp;Audrey Giocanti-Aurégan ,&nbsp;Pascale Massin","doi":"10.1016/j.diabet.2026.101728","DOIUrl":"10.1016/j.diabet.2026.101728","url":null,"abstract":"<div><h3>Aim</h3><div>To assess the outcomes of teleophthalmology-based diabetic retinopathy (DR) screening in individuals over 70 years within the OPHDIAT network and to compare them with those of patients aged 18–69 years.</div></div><div><h3>Methods</h3><div>A cohort of 16,459 diabetic patients, without known DR or with mild non-proliferative DR (NPDR), screened in 2024 in 32 OPHDIAT centers, was included and divided into two groups: &lt; 70 years (<em>n</em> = 13,639) and ≥ 70 years (<em>n</em> = 2,820). Two non-mydriatic retinal photographs per eye were analyzed by certified ophthalmologists.</div></div><div><h3>Results</h3><div>Among patients aged ≥70 years, 21.3% (95% CI: 19.8–22.8) had any DR, and 6.1% (95% CI: 5.2–6.9) were referred to an ophthalmologist for moderate NPDR or a more severe form of the disease, including suspected macular edema. These proportions did not significantly differ from those found in patients &lt; 70 years: 21.9% (95% CI: 21.2–22.6) and 6.1% (95% CI:5.6–6.5), respectively. Severe NPDR or proliferative DR were rare in both groups (1.0%, 95% CI: 0.6–1.4% <em>vs</em>. 1.7%, 95% CI: 1.5–1.9%, <em>P</em> &lt; 0.001). The proportion of ungradable images was higher in the group ≥70 year (14.4%, 95% CI:13.1–15.7% <em>vs</em>. 6.1%, 95% CI: 5.7–6.5%, <em>P</em> &lt; 0.001), particularly in phakic eyes, although 80% of patients had interpretable images for both eyes. Pupil dilation significantly improved image quality in this group. Screening also allowed detecting other ocular disorders, including age-related macular degeneration and glaucoma, which were more common in the group ≥ 70 years (2.1%, 95% CI: 1.5–2.6% <em>vs</em>. 0.6%, 95% CI: 0.4–0.7% <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Teleophthalmology-based DR screening appeared feasible and clinically relevant in patients aged ≥70 years, allowing identifying patients requiring ophthalmologic evaluation, while also detecting other age-related ocular diseases. Pupil dilation is recommended to optimize image quality in this population.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101728"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No association between carbohydrate-counting knowledge and disordered eating behaviors in adults with type 1 diabetes","authors":"Laura Albaladejo ,&nbsp;Melissa Ferguene ,&nbsp;Béatrice Genoux ,&nbsp;Lucien Marchand ,&nbsp;Hélène du Boullay ,&nbsp;Sandrine Lablanche ,&nbsp;Céline Vermorel ,&nbsp;Aurélie Gauchet ,&nbsp;Jean-Luc Bosson ,&nbsp;Cécile Bétry","doi":"10.1016/j.diabet.2026.101735","DOIUrl":"10.1016/j.diabet.2026.101735","url":null,"abstract":"<div><h3>Aims</h3><div>Carbohydrate counting enables flexible prandial insulin dosing in type 1 diabetes but remains cognitively demanding. Concerns persist that such sustained attention to food may contribute to disordered eating behaviors. The primary aim of this study was to examine whether carbohydrate-counting knowledge is associated with disordered eating behaviors.</div></div><div><h3>Methods</h3><div>This cross-sectional study (NCT07021456) was conducted online. Participants completed questionnaires assessing carbohydrate-counting knowledge (Gluciquizz), disordered eating behaviors (DEPS-R), and likely eating disorders (SCOFF-F). Additional questionnaires evaluated quality of life (ADDQoL), diabetes-related distress (PAID-5), and fear of hypoglycemia (HFS-II short form). Elevated DEPS-R was defined as a score ≥ 20, and likely eating disorders as SCOFF-F ≥ 2.</div></div><div><h3>Results</h3><div>A total of 100 adults with type 1 diabetes were included. No correlation was observed between Gluciquizz and DEPS-R (ρ = −0.03, 95% CI (−0.23 to 0.17), P = 0.73). Similarly, Gluciquizz scores did not differ between participants with SCOFF-F &lt; 2 and ≥ 2 (P = 0.745). Diabetes-related distress was significantly higher among participants with elevated DEPS-R scores (PAID-5 median 15 vs 8; P = 0.006), whereas ADDQoL and HFS-II did not differ significantly.</div></div><div><h3>Conclusion</h3><div>In this selected adult population with type 1 diabetes, carbohydrate-counting knowledge was not associated with disordered eating behaviors. However, positive DEB screening was linked with higher diabetes-related distress, supporting the importance of psychosocial assessment.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101735"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146000376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between glucagon-like peptide-1 receptor agonists and colorectal cancer survival: A population-based cohort study","authors":"Arnaud Dosda ,&nbsp;Grégoire Fauchier ,&nbsp;Nadia Sabbah ,&nbsp;Laurent Fauchier ,&nbsp;Thierry Lecomte ,&nbsp;Pierre Henri Ducluzeau","doi":"10.1016/j.diabet.2026.101734","DOIUrl":"10.1016/j.diabet.2026.101734","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP1-RA) use and all-cause mortality in patients with type 2 diabetes treated for colorectal cancer, using a real-world health database.</div></div><div><h3>Methods</h3><div>This retrospective cohort study was conducted using the TriNetX global health records network. Adult patients with type 2 diabetes diagnosed with colorectal cancer between 2010 and 2025 were included. Patients were divided into two cohorts based on GLP1-RA exposure versus other oral antidiabetic drugs. Propensity score matching was applied to balance covariates. Overall survival (primary outcome) and metastasis-free survival (secondary outcome) were analysed using Kaplan-Meier curves and Cox proportional hazards models.</div></div><div><h3>Results</h3><div>After propensity score matching, each cohort included 751 patients. Median follow-up period was 731 days in the GLP1-RA cohort and 779 days in the non-GLP1-RA cohort. GLP1-RA users had a significantly reduced all-cause mortality rate (11.5%) compared with non-users a (20.4%), with a hazard ratio of 0.58 (95%CI: 0.45–0.76; <em>P</em> &lt; 0.001). Metastasis-free survival rate were 5.3% in the GLP1-RA cohort versus 8.9% in the matched non-user cohort, with a hazard ratio of 0.60 (95%CI: 0.40–0.87; <em>P</em> = 0.01). The incidence of major adverse cardiovascular events (MACE) did not differ significantly between cohorts, with a hazard ratio of 0.84 (95%CI: 0.66–1.06; <em>P</em> = 0.16).</div></div><div><h3>Conclusions</h3><div>In this real-world cohort of diabetic patients treated for colorectal cancer, GLP1-RA therapy was associated with a significant improvement in overall survival. These findings support the continued use of GLP1-RA agents in this population and may provide reassurance to clinicians and patients regarding the safety and potential benefit of these agents following a colorectal cancer diagnosis.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101734"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When “good” comes too fast: rapid glycemic correction and the kidney: a “metabolic descent” hypothesis","authors":"Dured Dardari","doi":"10.1016/j.diabet.2026.101737","DOIUrl":"10.1016/j.diabet.2026.101737","url":null,"abstract":"","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101737"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146128413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fracture risk and treatment thresholds in patients with diabetes","authors":"Jakob Starup-Linde ,&nbsp;Katrine Hygum ,&nbsp;Henrik Støvring ,&nbsp;Jens-Erik Beck Jensen ,&nbsp;Pia Eiken ,&nbsp;Pernille Hermann ,&nbsp;Bente Langdahl ,&nbsp;Torben Harsløf","doi":"10.1016/j.diabet.2026.101722","DOIUrl":"10.1016/j.diabet.2026.101722","url":null,"abstract":"<div><h3>Aims</h3><div>Traditional risk factors underestimate fracture risk in individuals with diabetes. In this population-based case-control study we aimed to determine T-score thresholds for type 1 and 2 diabetes (T1D and T2D) with equivalent risk of fractures as that of individuals without diabetes and a T-score of -2.5.</div></div><div><h3>Research Design and Methods</h3><div>We collected dual energy x-ray absorptiometry (DXA) data (2000–2019), information on diagnoses (1977–2019) and redeemed medications (1997–2019) from the National Danish Registries which are linked by a unique identifier. Cases were individuals with the first incident major osteoporotic fracture (MOF) within two years before or one year after a DXA and controls were fracture free and matched on age, gender, and time period of the DXA. Logistic regression modelling was used in the case-control analysis.</div></div><div><h3>Results</h3><div>We identified 17,703 cases and 17,703 controls. T1D and T2D were associated with an increased risk of MOF (odds ratio: 1.8, 95 % CI:1.4;2.3 and 1.2, 95 % CI:1.1;1.3, respectively) adjusted for hip BMD. T1D and T2D patients had a similar risk of MOF at T-scores (total hip) = -1.4 and -2.1, respectively, as patients without diabetes with a T-score of -2.5. For hip fracture, the equivalent risk was correspondingly reached with T-scores of -1.9 and -1.6. Similar findings apply for femoral neck and lumbar spine BMD.</div></div><div><h3>Conclusions</h3><div>Compared to individuals without diabetes, fracture risk was increased in patients with T1D and T2D independent of BMD. Our study suggests that the T-score thresholds for treatment initiation in T1D and T2D should be increased.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"52 2","pages":"Article 101722"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145941345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}